EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

mRNA-Based Neoantigen Vaccines in Pancreatic Ductal Adenocarcinoma (PDAC)—A Promising Avenue in Cancer Immunotherapy

Jacek Kabut, Małgorzata Stopyra, Natalia Nafalska, Grzegorz J Stępień iD, Michał Miciak iD, Marcin Jezierzański, Tomasz Furgoł iD, Krzysztof Feret iD, Iwona Gisterek-Grocholska iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262210988 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Jacek Kabut und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Radiotherapy, Silesian Medical University, 40-514 Katowice, Poland. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Cancer Vaccines, Antigens, Neoplasm, Pancreatic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Medical University of Silesia, Katowice, Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies, with 5-year survival rates consistently below 5% despite advances in surgery, chemotherapy, and targeted therapy. Worldwide, PDAC remains highly lethal, with 458,918 new cases and 432,242 deaths in 2018—about a 94% mortality-to-incidence ratio. The limited therapeutic efficacy is largely attributed to the pronounced heterogeneity of the disease, late clinical presentation, and the strongly immunosuppressive tumor microenvironment. In recent years, mRNA-based vaccines encoding patient-specific neoantigens have emerged as a promising immunotherapeutic modality. By delivering tailored antigenic sequences, these vaccines are capable of eliciting potent cytotoxic T-cell responses against tumor-restricted epitopes, thereby enhancing tumor immunogenicity while minimizing off-target effects. This review summarizes the biological rationale underlying mRNA vaccination in PDAC, recent progress in preclinical and early clinical trials, and key obstacles related to antigen selection, delivery platforms, and the immunosuppressive stroma. The potential integration of neoantigen mRNA vaccines into multimodal therapeutic strategies, including immune checkpoint inhibition and chemotherapy, is also discussed, underscoring their prospective role in overcoming resistance mechanisms and improving clinical outcomes in PDAC. However, most current data come from early-phase trials, with long-term benefits yet unproven. Definitive conclusions on efficacy and survival await results from ongoing randomized studies expected by 2028–2029. Further progress in neoantigen identification, delivery systems, and combination strategies is crucial to fully harness mRNA vaccine potential in PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalCancer VaccinesAntigens, NeoplasmPancreatic NeoplasmsImmunotherapyRNA, MessengerHumansAnimalsTumor Microenvironment

Stichwörter der Autor:innen

immune checkpoint inhibitorsimmunotherapymRNA vaccinespancreatic ductal adenocarcinoma (PDAC)personalized cancer treatmenttherapeutic resistancetumor microenvironmenttumor neoantigens

Substanzen

Cancer VaccinesAntigens, NeoplasmRNA, Messenger

Autor:innen und Institutionen

  • Department of Oncology and Radiotherapy, Silesian Medical University, 40-514 Katowice, Poland.
  • Faculty of Medicine, Silesian Medical University, 41-800 Zabrze, Poland.
  • Faculty of Medicine, Medical University of Lodz, 90-419 Lodz, Poland.
  • Faculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland.
  • Faculty of Medicine, Academy of Silesia, 40-555 Katowice, Poland.

ORCID-Profile: Grzegorz J Stępień, Michał Miciak, Tomasz Furgoł, Krzysztof Feret, Iwona Gisterek-Grocholska

Förderung

  • the Medical University of Silesia, Katowice, Poland

Zitieren

APA

Kabut, J., Stopyra, M., Nafalska, N., Stępień, G. J., Miciak, M., Jezierzański, M., Furgoł, T., Feret, K., & Gisterek-Grocholska, I. (2025). mRNA-Based Neoantigen Vaccines in Pancreatic Ductal Adenocarcinoma (PDAC)—A Promising Avenue in Cancer Immunotherapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262210988

Vancouver

Kabut J, Stopyra M, Nafalska N, Stępień GJ, Miciak M, Jezierzański M, et al. mRNA-Based Neoantigen Vaccines in Pancreatic Ductal Adenocarcinoma (PDAC)—A Promising Avenue in Cancer Immunotherapy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262210988

BibTeX
@article{Kabut2025,
  author = {Kabut, Jacek and Stopyra, Małgorzata and Nafalska, Natalia and Stępień, Grzegorz J and Miciak, Michał and Jezierzański, Marcin and Furgoł, Tomasz and Feret, Krzysztof and Gisterek-Grocholska, Iwona},
  title = {mRNA-Based Neoantigen Vaccines in Pancreatic Ductal Adenocarcinoma (PDAC)—A Promising Avenue in Cancer Immunotherapy},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262210988}
}
Kostenlos starten →